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Abstract
Glycated albumin to glycated hemoglobin (GA/A1c) ratio is known to be inversely related with body mass index (BMI) and
insulin secretory capacity. However, the reasons for this association remain unknown. We aimed to investigate whether BMI
directly or indirectly influences GA/A1c by exerting effects on insulin secretion or resistance and to confirm whether these
associations differ according to glucose tolerance status. We analyzed a total of 807 subjects [242 drug-naı¨ve type 2
diabetes (T2D), 378 prediabetes, and 187 normal glucose tolerance (NGT)]. To assess the direct and indirect effects of BMI on
GA/A1c ratio, structural equation modeling (SEM) was performed. GA/A1c ratio was set as a dependent variable, BMI was
used as the independent variable, and homeostasis model assessment-pancreatic beta-cell function (HOMA-b), homeostasis
model assessment-insulin resistance (HOMA-IR), glucose level were used as mediator variables. The estimates of a direct
effect of BMI on GA/A1c to be the strongest in NGT and weakest in T2D (20.375 in NGT,20.244 in prediabetes, and20.189
in T2D). Conversely, the indirect effect of BMI on GA/A1c exerted through HOMA-b and HOMA-IR was not statistically
significant in NGT group, but significant in prediabetes and T2D groups (0.089 in prediabetes, 20.003 in T2D). It was found
that HOMA-b or HOMA-IR indirectly influences GA/A1c in T2D and prediabetes group through affecting fasting and
postprandial glucose level. The relationship between GA/A1c and BMI is due to the direct effect of BMI on GA/A1c in NGT
group, while in T2D and prediabetes groups, this association is mostly a result of BMI influencing blood glucose through
insulin resistance or secretion.
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Introduction
Until now, the gold standard parameter for monitoring
glycemic excursion has been glycated hemoglobin (A1c). However,
A1c does not provide accurate information following earlier
changes in glycemic control after drug intervention or in various
conditions affecting the lifespan of red blood cells [1–3]. Although
glycated albumin (GA), a useful glycemic index for intermediate
periods over 2–4 weeks, may be viewed as an adjunct to A1c, it is
gaining popularities during the transition between medications for
intensive treatment or for diabetes management at a monthly level
[4–6]. In addition, serum GA has been shown to be a superior
indicator for plasma glucose variability to A1c [7].
Recently, not only GA but also the ratio of GA to A1c (GA/
A1c) is expected to be a new glucose control marker [8]. However,
notwithstanding the pathologic condition affecting albumin
metabolism such as thyroid dysfunction, nephrotic syndrome, or
liver cirrhosis [4], the physiologic variables such as age or body
mass index (BMI) [9] make the GA/A1c ratio a little unpredict-
able in clinical practice. Among them, several studies have
suggested a negative correlation between BMI and serum GA in
non-diabetic children, as well as in adult diabetic patients [9–11].
However, conflicting result was observed in Kyushu and Okinawa
Population Study, which reported no significant association
between GA and BMI in type 2 diabetic subjects [12]. In spite
of the discordant results on the association between GA/A1c ratio
and BMI in especially diabetic patients, there has been no study in
the literature to date focusing on the relationship between GA/
A1c ratio and BMI according to glucose tolerance status.
Moreover, we have demonstrated that insulin secretory functions,
such as homeostasis model assessment-pancreatic beta-cell func-
tion (HOMA-b) and insulinogenic index, but not insulin
resistance, are negatively associated with GA/A1c ratio in patients
with type 2 diabetes (T2D) [13]. Increase in BMI generally leads to
not only insulin resistance but also compensatory elevated insulin
secretion, and insulin secretion is inversely associated with GA/
A1c; therefore, a decrease in GA/A1c is expected following
elevated BMI. In other words, it could be hypothesized that the
influence of BMI on GA/A1c level might be mediated through
elevated insulin secretion. However, there are few studies
reporting the relationship between GA/A1c ratio and BMI in
association with insulin secretory function, insulin resistance, and
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serum glucose level. Therefore, this study aimed to observe the
association between BMI, insulin secretion, resistance, blood
glucose, and GA/A1c according to glucose tolerance; furthermore,
it employed structural equation modeling (SEM), which can
differentiate direct and indirect effects, to identify whether the
characteristics of aforementioned associations are different among
subjects with normal glucose tolerance, prediabetes, and T2D.
Materials and Methods
Ethics Statement
The study was carried out according to the Declaration of
Helsinki and the International Conference on Harmonization
Good Clinical Practice Principles. The protocol was approved by
the independent institutional review board at Yonsei University
College of Medicine. All enrolled subjects provided written
informed consent.
Study population and design
In this clinical, cross-sectional study, we analyzed patients who
satisfied certain criteria based on their medical records. We
included patients enrolled in the diabetes registry of Severance
Diabetes Center between June 2008 and February 2012; only first-
time visitors to the center and subjects who had been tested for
GA, HbA1c, plasma glucose and C-peptide were included.
Exclusion criteria included a history of use of hypoglycemic or
lipid-lowering agents, severe liver or kidney disease (chronic kidney
disease $ stage 3), active thyroid disorders, pregnancy, steroid
therapy, heavy alcohol usage, Type 1 diabetic patients (C-peptide
,0.5 ng/mL) and malignant disease.
To investigate the relationship between BMI and GA/A1c ratio
stratified by degree of insulin secretory function and insulin
resistance, patients were classified into 3 groups based on the
American Diabetes Association 2011 guidelines: T2D
(A1c$6.5%), increased risk for diabetes (A1c= 5.7–6.4%, de-
scribed as prediabetes hereon), and normal glucose tolerance
(NGT) (A1c#5.6%) [3,14]. Anthropometric measurements were
taken with patients wearing light clothing and no shoes. Waist
circumference was measured with the tape measure placed
horizontally at the level of the umbilicus while the participant
gently exhaled. BMI was calculated as weight in kilograms divided
by the square of height in meters. The study protocol was
approved by the Ethics Committee of Yonsei University College of
Medicine.
Laboratory measurements
Blood samples were collected at 0 and 90 mins (postprandial)
for glucose, insulin and C-peptide analyses. Plasma glucose levels
were measured using the glucose oxidase method (Hitachi 747
automatic analyzer, Hitachi Instruments Service, Tokyo, Japan).
Serum GA levels were measured using the enzymatic method and
a Hitachi 7699 P module autoanalyzer (Hitachi Instruments
Service). A1c levels were measured by high-performance liquid
chromatography using a Variant II Turbo (Bio-Rad Laboratories,
Hercules, CA, USA). Serum insulin and C-peptide levels were
measured in duplicate by immunoradiometric assay (Beckman
Coulter, Fullerton, CA, USA).
Basal b-cell function and insulin resistance were assessed by
HOMA-b and insulin resistance was assessed by homeostasis
model assessment-insulin resistance (HOMA-IR).
HOMA-b~
fasting insulin mIU=mLð Þ|20
0:055551|fasting glucose mg=dLð Þ{3:5
HOMA-IR~
fasting insulin mIU=mLð Þ|20
0:055551|fasting glucose mg=dLð Þ{3:5
Statistical analyses
All continuous variables are shown as mean 6 standard
deviation. Analysis of variance (ANOVA) followed by post hoc
analysis using Bonferroni correction was used to compare variables
across multiple groups. The relationships between clinical and
laboratory variables were evaluated using univariate Pearson’s
correlation analysis. To correct for skewed distributions, HOMA-
b, HOMA-IR were logarithmically transformed. Then SEM
analyses were performed to assess the direct and indirect effects of
between variables. Values of variables used in SEM were
standardized due to the wide ranges encountered for these
variables. The standardization method for a dataset of size k with
mean value m and variance s2 is as follows:
X1,X2,:::,XK * m,s2
 
F1~
Xi{m
s
,i~1,2,:::,K:
Fi is a standardized value based on the mean and standard
deviation.
To assess the direct effect of BMI on GA/A1c ratio independent
of the indirect effect of BMI on GA/A1c ratio mediated by other
variables, a statistical analysis was performed using SEM and path
diagram analysis by IBMH SPSSH Amos (Figure S1) [15]. Briefly,
GA/A1c ratio was set as a dependent variable, and BMI was set as
an independent variable. HOMA-b, HOMA-IR, fasting glucose
and postprandial glucose were used as mediator variables which
are associated with each other and with GA/A1c ratio,
respectively. The purpose of this analysis was to observe whether
the independent variables—in this case, BMI—have direct or
indirect effects (through mediator variables) on GA/A1c ratio, the
dependent variable. In other words, although one independent
variable may seem to directly influence GA/A1c ratio, a path
diagram analysis may reveal that this relationship is in fact due to
another independent variable that acts as a mediator between the
first independent variable and GA/A1c ratio. For this study, we
proposed the following path diagrams (Figure 1) which was
examined for each group. P values less than 0.05 were considered
statistically significant. All data were analyzed using PASW
Statistics version 18 (SPSS Inc, Chicago, IL, USA).
Results
Baseline Characteristics of Patients
A total of 807 patients (242 with T2D, 378 with prediabetes,
and 187 with NGT) satisfied the inclusion criteria of this study.
Table 1 summarizes the demographic and clinical characteristics
of the patients. The mean age of all patients was 55.26 years, and
the mean GA/A1c ratio was 2.2060.41. BMI, waist-hip ratio, and
body weight were significantly higher in the T2D group, followed
by the prediabetes and the NGT groups. GA and GA/A1c ratio
were significantly higher in the T2D group than other two groups.
HOMA-b (%) was significantly higher (P,0.001) in the predia-
betes group (80.55654.17), followed by the NGT (76.96654.10)
BMI Affect GA Differently as per Glucose Tolerance
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Figure 1. Structural equation models for the GA/A1c ratio.
doi:10.1371/journal.pone.0089478.g001
Table 1. Baseline characteristics.
Total N=807 NGT n=187 Prediabetes n=378 Diabetes n=242 P value
Sex: M/F (male %) 432/375 (53.5%) 93/94 (49.7%) 198/180 (52.4%) 141/101 (58.3%) 0.177
Age (year) 55.26611.51 49.02611.92{` 58.1969.84{# 55.53611.76`# ,0.001
Height (cm) 165.0468.52 166.0568.58 164.8068.15 164.6269.01 0.171
Weight (Kg) 67.19612.48 63.85611.92{` 67.09612.31{# 69.93612.55`# ,0.001
BMI (kg/m2) 24.5863.45 23.0562.96{` 24.6063.40{# 25.7563.41`# ,0.001
WHR 0.8960.06 0.8660.08{` 0.8960.05{# 0.9160.05`# ,0.001
SBP (mmHg) 126.14616.68 119.16613.91{` 125.63615.92{# 132.29617.53`# ,0.001
DBP (mmHg) 78.41611.15 76.44610.23` 78.21611.06 80.21611.72` 0.002
HbA1c (%) 6.5561.52 5.4760.16{` 5.9860.22{# 8.2761.81`# ,0.001
GA (%) 14.7666.28 11.2761.48{` 12.3461.77{# 21.1068.07`# ,0.001
GA/A1c 2.2060.41 2.0660.28` 2.0660.27# 2.5260.52`# ,0.001
Glucose at 0 min (mg/dL) 111.57636.93 88.9868.14{` 99.30611.27{# 147.34649.25`# ,0.001
Glucose at 90 min (mg/dL) 164.32678.34 112.79633.61{` 135.21644.55{# 241.04681.96`# ,0.001
C-peptide at 0 min (mg/L) 2.2661.12 1.8360.92{` 2.2461.08{# 2.5661.19`# ,0.001
C-peptide at 90 min (mg/L) 7.1563.66 6.6364.08{ 7.7563.77{# 6.5263.12# ,0.001
Insulin at 0 min (mIU/mL) 7.9865.91 5.5563.60{` 7.7165.13{# 9.8367.39`# ,0.001
Insulin at 90 min (mIU/mL) 50.63646.97 35.28640.39{` 52.56650.24{ 55.41643.47` ,0.001
HOMA-b (%) 71.49655.85 76.96654.10` 80.55654.17# 53.86655.61`# ,0.001
HOMA-IR 2.3462.20 1.2760.84{` 1.9361.40{# 3.6163.04`# ,0.001
Cholesterol (mg/dL) 188.83638.92 186.17635.10 188.90638.84 190.74641.74 0.488
LDL (mg/dL) 110.23635.19 109.82630.74 112.68634.94 106.69638.47 0.117
HDL (mg/dL) 51.26619.27 52.18613.67 50.82617.39 51.23625.00 0.735
Fasting TG (mg/dL) 131.32698.59 105.75669.75` 117.80657.77# 172.376145.27`# ,0.001
Postprandial TG (mg/dL) 156.866117.63 104.43684.12` 124.45663.15# 206.916147.97`# ,0.001
Hb (g/dL) 14.2161.49 14.1361.42 14.1061.49# 14.4761.54# 0.01
Protein (g/dL) 6.9560.42 6.8060.37{` 6.9260.41{# 7.1160.43`# ,0.001
Albumin (g/dL) 4.3760.33 4.3060.32` 4.3360.29# 4.4960.35`# ,0.001
Creatinine (mg/dL) 0.8460.31 0.7760.17{` 0.8660.40{ 0.8760.22` 0.003
Data presented as n (%) or mean 6 standard deviation.
{: The difference between NGT and Prediabetes : p,0.05 after Bonferroni correction.
`: The difference between NGT and Diabetes : p,0.05 after Bonferroni correction.
#: The difference between Prediabetes and Diabetes : p,0.05 after Bonferroni correction.
Abbreviations: NGT, normal glucose tolerance; BMI, body mass index; WHR, waist-to-hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c,
glycated hemoglobin; GA, glycated albumin; GA/A1c, ratio of glycated albumin to glycated hemoglobin; HOMA-b, homeostasis model assessment- pancreatic beta-cell
function; HOMA-IR, homeostatsis model assessment-insulin resistance; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglyceride.
doi:10.1371/journal.pone.0089478.t001
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and the T2D (53.86655.61) groups. HOMA-IR was significantly
higher (P,0.001) in the T2D group (3.6163.04), followed by the
prediabetes (1.9361.40) and the NGT (1.2760.84) groups.
Correlation of GA/A1c Ratio and BMI in Diabetic,
Prediabetic, and NGT Patients
To assess the correlation between GA/A1c ratio and BMI
according to glucose tolerance status, we performed Pearson
correlation analysis (Table 2). The negative association between
GA/A1c ratio and BMI was the most prominent in the NGT
group. (NGT: R=20.383, P,0.001; prediabetes: R=20.221,
P,0.01; T2D: R=20.181, P,0.001). There was a significant
positive correlation between fasting, postprandial glucose and
GA/A1c ratio in the prediabetes and the T2D groups. Moreover,
a negative relationship between GA/A1c ratio and HOMA-b was
significant in the T2D group and the prediabetes groups but not in
the NGT group (prediabetes: R=20.342, P,0.001; and T2D:
R=20.322, P,0.001). The relationship between insulin resis-
tance and GA/A1c ratio was statistically significant only in the
prediabetes groups (R=20.138, P=0.007).
Decomposition of Direct and Indirect Effect of BMI on
GA/A1c Ratio
SEM was employed to separately analyze the direct effects of
BMI on GA/A1c ratio (Figure 1). Figure 2 depicts the SEM for
GA/A1c ratio in each glucose tolerance group. Using this model,
the estimates of a direct effect of BMI on GA/A1c were 20.375
(P,0.001) in the NGT group, 20.244 (P,0.001) in the
prediabetes group, and 20.189 (P=0.002) in the T2D group. In
the NGT group, there was no significant indirect effect of BMI on
GA/A1c ratio. In contrast, in prediabetes and T2D group, the
indirect effects of BMI on GA/A1c ratio which is mediated by
HOMA-bRfasting glucose or postprandial glucose and HOMA-
IRRfasting glucose or postprandial glucose were significant.
However, in the prediabetes and the T2D groups, these indirect
effects of BMI on GA/A1c ratio were relatively weak (0.089 in the
prediabetes group; 20.003 in the T2D group). In each group, the
variables which were significantly associated with GA/A1c ratio
was only BMI in the NGT group (estimate of effect: 20.375,
P,0.001), while fasting glucose, postprandial glucose, and BMI in
the prediabetes and T2D groups. In addition, in prediabetes and
T2D group, the influence of fasting and prostprandial glucose
parameters on GA/A1c was greater than that of BMI.
(BMIRGA/A1c: 20.244, Postprandial glucoseR GA/A1c:
0.173, Fasting glucoseR GA/A1c: 0.499 in prediabtes group;
BMIRGA/A1c: 20.189, Postprandial glucoseR GA/A1c: 0.300,
Fasting glucoseR GA/A1c: 0.220 in T2D group). The degree of
effect of BMI on HOMA-b was the most prominent in NGT,
followed by the prediabetes and the T2D groups, in that order.
However, a direct effect of HOMA-b or HOMA-IR on GA/A1c
was not observed in any groups.
Discussion
The present study represents the first of its kind to investigate
the relation between BMI and GA/A1c according to glucose
tolerance status. Our results indicated that inverse association
between BMI and GA/A1c ratio was observed in all glucose
tolerance status, which was strongest in NGT group, followed by
the prediabetes and the T2D groups, in that order. Furthermore,
using SEM, we found that the variables influencing GA/A1c ratio
was different according to glucose tolerance status; only BMI in
the NGT group, BMI, postprandial glucose and fasting glucose in
the prediabetes and T2D groups. The results suggested that
although it is true that BMI is inversely related to GA/A1c ratio,
the ratio is under greater influence by glucose parameters than by
BMI in prediabetes or T2D; therefore, this suggests that while
GA/A1c cannot be an accurate index of glycemic control status in
NGT, it may be a significant index in prediabetes or diabetes
regardless of BMI.
Previous studies have indicated that obesity is negatively
associated with GA and GA/A1c ratio. However, the underlying
mechanisms of this relationship remain to be answered, and they
were not fully evaluated in subjects with prediabetes or NGT.
Koga et al. demonstrated that obesity and its related chronic
inflammation are involved in lower serum GA levels [16]. On the
other hand, other studies have suggested that the negative
association of obesity with GA is due to abnormal albumin
concentrations in obese subjects [17]. However, Nishimura et al
indicated that obese children had higher serum albumin than non-
obese children, and Koga et al. found no correlation between BMI
and albumin concentrations [9,16]. Based on these unclear
answers for the mechanism of the association between BMI and
GA/A1c ratio, we tried to explain this mechanism with respect to
BMI, a representative parameter for obesity, and insulin secretory
function. In accordance with the increase of BMI, insulin secretory
function might be also increased to overcome the insulin
resistance. However, the degree of increase of insulin secretory
function required to overcome insulin resistance would differ
according to various glucose tolerance status. Therefore, the effect
of BMI on GA/A1c, which is negatively associated with insulin
secretory function [18], would also differ according to glucose
tolerance status. Based on these findings, we hypothesized that the
magnitude of negative influence of BMI on GA/A1c ratio might
be dependent on gluco-insulin homeostasis, especially on insulin
secretory function compensating for insulin resistance. Therefore,
we investigated the association between BMI and GA/A1c ratio
according to glucose tolerance status. To address these questions,
we recruited drug-naive subjects with NGT, prediabetes, and
T2D. The present study represents the first of its kind to
Table 2. Correlations between GA/A1c ratio and other
variables.
GA/A1c
Variables NGT (n=187)
Prediabetes
(n=378) Diabetes (n=242)
Age NS 0.151(0.003) NS
WHR NS 20.178(0.001) NS
BMI 20.383(,0.001) 20.221(,0.001) 20.181(0.005)
A1c 20.183(0.015) 0.188(,0.001) 0.423(,0.001)
Glycated
albumin
0.971 (,0.001) 0.963 (,0.001) 0.807(,0.001)
Glucose at 0 minNS 0.293(,0.001) 0.459(,0.001)
Glucose at
90 min
NS 0.258(,0.001) 0.463(,0.001)
LN HOMA-b NS 20.342 (,0.001) 20.332(,0.001)
LN HOMA-IR NS 20.138 (0.007) NS
Values are Pearson correlation coefficients between variables and GA/A1c ratio.
Abbreviations: NGT, normal glucose tolerance; BMI, body mass index; WHR,
waist-to-hip ratio; A1c, hemoglobin A1c; GA/A1c, ratio of glycated albumin to
glycated hemoglobin; LN HOMA-b, log transformed homeostasis model
assessment-pancreatic beta-cell function; LN HOMA-IR, log transformed
homeostatis model assessment-insulin resistance; NS, not significant.
doi:10.1371/journal.pone.0089478.t002
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Figure 2. Structural equation models for the GA/A1c ratio in NGT (A), prediabetes (B) and diabetes group (C). *P,0.05; **P,0.01;***
P,0.001.
doi:10.1371/journal.pone.0089478.g002
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investigate the relation between BMI and GA/A1c ratio according
to glucose tolerance status. The results demonstrated four main
findings with respect to correlations with the GA/A1c ratio.
First, the inverse association between BMI and GA/A1c ratio
was observed in all glucose tolerance status, which was strongest in
NGT group, followed by the prediabetes and the T2D groups.
The reason for the different degrees of effect of BMI on GA/A1c
ratio by glucose tolerance status groups may be a greater influence
of BMI on factors other than GA/A1c ratio in the prediabetes and
the T2D groups. A recent, large population-based study [12]
showed that BMI had no effect on GA levels in subject with T2D,
even when including patients with high BMI. This unexpected
result suggests that BMI exerts influence on other factors besides
GA; consequently, the association between BMI and GA may
seem to have been weakened especially in subjects with T2D.
Second, using SEM analysis, we found that HOMA-b does not
significantly affect GA/A1c. Similar to previous studies [14], a
simple correlation analysis found a negative correlation between
HOMA-b and GA/A1c ratio. However, when we analyzed SEM
which excluded other factors that influences GA/A1c ratio, we
observed that HOMA- b does not directly affect GA/A1c ratio.
These findings explain that the negative association between
HOMA-b and GA/A1c ratio shown in previous studies [13,14]
may be attributed to the indirect effect of the glucose variability of
fasting and postprandial glucose mainly caused by the decline of
insulin secretory function [19] Third, the variables influencing
GA/A1c ratio were different according to glucose tolerance status
groups. In the NGT group, only BMI significantly influenced GA/
A1c ratio, whereas in the prediabetes and the T2D groups, fasting
glucose and postprandial glucose also influenced GA/A1c ratio.
The absence of influence of glucose level in the NGT group may
be explained by the following. The pathophysiology of T2D is
characterized by insulin resistance and impaired compensatory
insulin secretion. Therefore, in T2D, insulin secretion is unable to
quickly compensate for insulin resistance, leading to increased
postprandial sugar levels and greater elevation of GA (known to be
an index reflecting postprandial glycemic status) compared to A1c.
However, in patients with NGT with intact insulin secretory
function, excessive postprandial elevation of blood glucose is not
observed, and a disproportionate increase of GA compared to A1c
does not occur, resulting in loss of association between GA/A1c
ratio and insulin secretory function. Furthermore, we have
confirmed that only BMI held a significant influence over GA/
A1c ratio in NGT while in prediabetes and T2D, both glucose
parameters and BMI significantly inflenced GA/A1c ratio, with
the former providing a greater influence. These findings may be
the basis of explaining the clearer effect of BMI on GA/A1c ratio
in NGT group. Fourth, the effect of HOMA-b on fasting glucose
was the most prominent in the NGT group, followed by the
prediabetes group and the T2D groups. Also, the effect of
HOMA-b on postprandial glucose was the most prominent in the
T2D group, followed by the prediabetes and the NGT groups.
This result is consistent with the previous study because early-
phase insulin secretion and glucose-stimulated insulin secretion are
decreased in the NGT and the prediabetes groups, which mainly
contribute to the increase of fasting glucose [20]. On the other
hand, because the overall insulin secretory function declines in
T2D group, the insulin secretory function might influence the
postprandial glucose as well as the fasting glucose compared with
other groups. These findings provide important clues to the
greater understanding of the concept of GA/A1c ratio with
reference to glucose parameter.
A recent study has demonstrated that GA may be lower than
the actual plasma glucose levels in NGT patients who have
elevated body fat content; furthermore, the actual plasma glucose
levels may be underestimated in obese patients when monitoring
glycemic control with GA alone [21]. These data corresponded
well to our result, which showed a strong association between BMI
and GA/A1c ratio in NGT patients. However, in our study, the
association between BMI and GA/A1c ratio was relatively weak in
the prediabetes and the T2D groups. Instead, GA/A1c ratio was
more strongly related with increasing glucose level. Therefore,
when monitoring glycemic control with GA, it is necessary to
consider the effect of BMI on GA/A1c ratio. Nonetheless, because
the effect of BMI on GA/A1c ratio is relatively weaker than those
of the glucose parameters in the T2D group, GA/A1c ratio well
reflect the status of glucose control even in high BMI.
Our study has some limitations. First, we could not measure
body composition, such as fat mass, or inflammatory cytokines
(e.g. CRP), which may explain the mechanism of the negative
association between BMI and GA/A1c ratio. Second, the cross-
sectional study design precluded observations of future variations.
Third, we could not adjust for known independent influencing
factors of GA, such as triglyceride, smoking status, and age.
Despite all these weaknesses, however, this study has found that
the direct effect of HOMA-b alone on GA/A1c ratio is not
significant in diabetic patients, contrary to the findings of previous
studies which suggested an inverse association between GA/A1c
ratio and HOMA-b. The previously found association between
these two factors is more likely to be mediated through fasting
and/or postprandial glucose. Furthermore, the factors influencing
GA/A1c ratio is different according to glucose tolerance status.
Insulin secretory function is preserved in the NGT, resulting in less
glucose excursion; consequently, GA does not increase compared
to A1c, which explains the fact that the ratio is not associated with
other glucose parameters (fasting/postprandial glucose, HOMA-b,
etc.) in the NGT group. Fasting glucose exerted the greatest
influence on GA/A1c ratio in the prediabetes group, whereas
postprandial glucose was the greatest contributing factor to GA/
A1c ratio in the T2D group.
In conclusion, the inverse association between GA/A1c and
BMI is the result of different mechanisms according to glucose
tolerance status: in the NGT group, it is due to the direct
association between BMI and GA/A1c, while in the prediabetes
and T2D group, GA/A1c ratio was influenced by glucose
parameters in addition to BMI, resulting in less influence of
BMI on the ratio compared to NGT. These findings suggest that
GA may underestimate the actual glycemic status in obese
patients; however, this discrepancy tends to disappear as the
subject reaches closer to T2D.
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